Hizoh Istvan, Gulyas Zalan, Domokos Dominika, Banhegyi Gyongyver, Majoros Zsuzsanna, Major Laszlo, Ratkai Timea, Kiss Robert Gabor
Department of Cardiology, Medical Center, Hungarian Defense Forces, Budapest, Hungary.
Department of Cardiology, Medical Center, Hungarian Defense Forces, Budapest, Hungary.
Cardiovasc Revasc Med. 2017 Jan-Feb;18(1):33-39. doi: 10.1016/j.carrev.2016.10.002. Epub 2016 Oct 14.
The mortality benefit of transradial primary PCI has been shown by several studies. Previous risk models have not considered access site as a candidate predictor and many of them were developed using low risk populations of randomized trials. We conducted a prospective cohort study to construct and validate an admission risk model including access site as candidate variable for predicting 30-day mortality after primary PCI.
We analyzed data of 1255 patients using variables readily available at presentation. Predictor selection was based on backward logistic regression combined with bootstrap resampling. The model has been validated internally and temporally externally.
Thirty-day mortality was independently associated with older age, faster heart rate, need for life support on or prior to admission, and femoral access while it was inversely related to systolic blood pressure. ROC curve analysis revealed high discriminatory power, which was preserved in the validation set (c-statistic: 0.88 and 0.87, respectively). For the new score the acronym ALPHA (Age, Life support, Pressure, Heart rate, Access site) has been coined. Compared with previous models, our score achieved the highest c-statistic (0.87) followed by the GRACE 2.0 (0.86), APEX-AMI (0.86), and CADILLAC (0.85) models, the other scoring systems (TIMI, Zwolle, and PAMI) performed less well. The ALPHA, GRACE 2.0, APEX-AMI, and CADILLAC models predicted 30-day mortality better than the PAMI score (p=0.005, 0.004, 0.01, and 0.02, respectively).
Using this tool, mortality risk may be precisely assessed at admission and patients who may benefit most from transradial access may be identified.
多项研究已表明经桡动脉行直接经皮冠状动脉介入治疗(PCI)的死亡率获益。既往风险模型未将入路部位视为候选预测因素,且其中许多模型是使用随机试验的低风险人群开发的。我们进行了一项前瞻性队列研究,以构建和验证一个入院风险模型,该模型将入路部位作为预测直接PCI术后30天死亡率的候选变量。
我们使用就诊时 readily available 的变量分析了1255例患者的数据。预测因素的选择基于向后逻辑回归结合自助重抽样。该模型已在内部和外部进行了验证。
30天死亡率与年龄较大、心率较快、入院时或入院前需要生命支持以及股动脉入路独立相关,而与收缩压呈负相关。ROC曲线分析显示具有高辨别力,在验证集中得以保留(c统计量分别为0.88和0.87)。对于新评分,创造了首字母缩写词ALPHA(年龄、生命支持、血压、心率、入路部位)。与既往模型相比,我们的评分获得了最高的c统计量(0.87),其次是GRACE 2.0(0.86)、APEX-AMI(0.86)和CADILLAC(0.85)模型,其他评分系统(TIMI、Zwolle和PAMI)表现较差。ALPHA、GRACE 2.0、APEX-AMI和CADILLAC模型预测30天死亡率优于PAMI评分(p分别为0.005、0.004、0.01和0.02)。
使用该工具,可在入院时精确评估死亡风险,并识别可能从经桡动脉入路中获益最大的患者。